Retatrutide, a novel dual agonist of the GLP-1 receptor and glucose-dependent secreted polypeptide (GIP) binding site , is demonstrating promising data in early clinical studies. Ongoing inquiry suggests https://shopretatrutidepeptide.com/retatrutide-research-knowledge-hub/